Maverick Spend

‘Strategic Sourcing’ has played a key role in the success of procurement teams. A dent in this key game plan is “maverick spending.”

Written byAmit Pratap Singh Rathore
| 4 min read
Register for free to listen to this article
Listen with Speechify
0:00
4:00

How It Happens and How to Counteract

Procurement is rising on the priority lists of both corporations and governments. The two foremost examples that I can think of are:

  • In December 2014, the US government reported a reduction of more than USD 55 billion in contract savings in fiscal year 2013 over the previous year. The savings was part of a four-year decrease in the cost of federal contracting.
  • Novartis, a global healthcare company, has reported procurement savings of USD 1.6 billion in 2014 and is expected to see even greater procurement savings in 2015.

‘Strategic Sourcing’ has played a key role in the success of procurement teams in both of the above-mentioned cases. A dent in this key game plan is “maverick spending.”

Maverick spending can be defined as a purchase made outside of the preferred route. These are ad-hoc purchases, made outside a negotiated contract with a preferred supplier. I will discuss maverick spending and countermeasures in relation to the pharmaceutical industry in order to understand it better.

How much does an organization really lose?

Direct capital loss

To continue reading this article, sign up for FREE to
Lab Manager Logo
Membership is FREE and provides you with instant access to eNewsletters, digital publications, article archives, and more.

CURRENT ISSUE - October 2025

Turning Safety Principles Into Daily Practice

Move Beyond Policies to Build a Lab Culture Where Safety is Second Nature

Lab Manager October 2025 Cover Image